FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study

Journal of Clinical Oncology

Volumn 22, Issue 2, 2004, Pages 229-237

  Tournigand, Christophe ^b   André, Thierry ^b   Achille, Emmanuel ^b   Lledo, Gérard ^b   Flesh, Michel ^b   Mery Mignard, Dominique ^b   Quinaux, Emmanuel ^b   Couteau, Corinne ^b   Buyse, Marc ^b   Ganem, Gérard ^b   Landi, Bruno ^b   Colin, Philippe ^b   Louvet, Christophe ^b   De Gramont, Aimery ^a  

^a HÔPITAL SAINT ANTOINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PLATINUM COMPLEX;

ALOPECIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADULT; AGED; COLORECTAL TUMOR; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS;

EID: 1342290189     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.113     Document Type: Article

References (31)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999
2. Glimelius B, Hoffman K, Graf W, et al: Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 73:556-562, 1994
3. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer, evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
4. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15:808-815, 1997
5. de Gramont A, Louvet C, André T, et al: A simplified bimonthly regimen with leucovorin and 5-fluorouracil for metastatic colorectal cancer. Proc Am Soc Clin Oncol 16:287a, 1997 (abstr 1019)
6. de Gramont A, Louvet C, André T, et al: Infusional 5-fluorouracil: the bimonthly approach. In Bleiberg H. et al (ed): Colorectal Cancer, a clinical guide to therapy. London, Dunitz, 2002, pp 463-466
7. Cunningham D, Pyrh'nen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1993
8. Rougier P, Van Custem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
9. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
10. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047, 2000
11. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
12. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: oxaliplatin or CPT-11 plus 5-fluorouracil/leucovorin or oxaliplatin plus CPT-11 in advanced colorectal cancer. Updated efficacy and quality of life data from an intergroup study. Proc Am Soc Clin Oncol 22:252, 2003 (abstr 1009)
13. Raymond E, Buquet-Fagot C, Djelloul S, et al: Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs 8:876-885, 1997
14. de Gramont A, Vignoud J, Tournigand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33:214-219, 1997
15. André T, Bensmaine M, Louvet C, et al: Multicentrer phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17:3560-3568, 1999
16. Maindrault-Goebel F, Louvet C, André T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5FU regimen as second line therapy for metastatic colorectal cancer. Eur J Cancer 35:1338-1342, 1999
17. Maindrault-Goebel F, Louvet C, André T, et al: High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouacil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37: 1000-1005, 2001
18. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48h 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 11:1477-1483, 2000
19. André T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35:1343-1347, 1999
20. MacDonald J, Haller D, Mayer R: Grading of toxicity, in MacDonald J, Haller D, Mayer R (eds): Manual of Oncologic Therapeutics. Philadelphia, PA, Lippincott, 1995, pp 519-523
21. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
22. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trials. Biometrics 31:103-115, 1975
23. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982
24. Kaplan EL, Meier P: Non parametric estimation from incomplete observations: J Am Stat Assoc 53:457-481, 1958
25. Mantel N, Haenzel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
26. Cox DR: Regression models and life-tables. J R Stat Soc 348:187-220, 1972
27. Rothenberg ML, Oza AM, Burger B, et al: Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5FU, and leucovorin. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1011)
28. Maindrault F, Louvet C, André T, et al: Time of disease control to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer based on 5-flourouracil, oxaliplatin and irinotecan. Proc Am Soc Clin Oncol 20:146a, 2001 (abstr 581)
29. André T, Figer A, Cervantes A, et al: FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized Optimox study. Proc Am Soc Clin Oncol 22:253, 2003 (abstr 1016)
30. Mabro M, Artru P, Flesch M, et al: Irinotecan, 5-fluorouracil infusion and leucovorin (FOLFIRI-3) in pretreated patients with metastatic colorectal cancer: results of a multicenter phase II study. Proc Am Soc Clin Oncol 22:280, 2003 (abstr 1125)
31. Douillard JY, Sobrero A, Carnaghi C, et al: Metastatic colorectal cancer: Integrating irinotecan into combination and sequential chemotherapy. Ann Oncol 14:7-12, 2003 (suppl 2)